Catalent Inc
NYSE:CTLT
Net Margin
Catalent Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Catalent Inc
NYSE:CTLT
|
11.5B USD |
-9%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
765.4B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
373.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
209.1B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.1B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
166.6B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
203.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
163.5B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
138.7B USD |
13%
|
Catalent Inc
Glance View
In the intricate world of pharmaceuticals, Catalent Inc. stands out as a critical player, quietly orchestrating the development and delivery of drugs that impact lives globally. Founded in 2007, Catalent has carved a niche in the field through its commitment to advanced drug delivery technologies and supply chain services. As a contract development and manufacturing organization (CDMO), the company offers a suite of services to pharmaceutical and biotechnology firms, including drug formulation and delivery optimization, biologics development, and clinical supply services. With over 30 facilities worldwide, it acts as a pivotal partner to firms seeking to enhance the effectiveness and accessibility of their therapies without grappling with the complexities of manufacturing and logistics themselves. The crux of Catalent’s business model lies in enabling its clients to bring medical innovations to market effectively and efficiently. By leveraging its expertise in areas such as oral, injectable, and inhalable delivery forms, Catalent ensures that drugs are not only manufactured to the highest standards but are also optimized for patient adherence and effectiveness. The company earns its revenues through long-term contracts by offering continuous support from the early stages of drug development through to commercialization. Catalent drives its growth by staying ahead of industry trends, investing heavily in biologics and gene therapy, which represent high-growth areas in the pharmaceutical industry, thereby ensuring its relevance and significance in an ever-evolving healthcare landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Catalent Inc's most recent financial statements, the company has Net Margin of -9.3%.
You don't have any saved screeners yet